시장보고서
상품코드
1821540

세계의 암종양 프로파일링 시장 보고서(2025년)

Cancer Tumor Profiling Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

암종양 프로파일링 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 13.8%로 251억 2,000만 달러로 성장합니다. 예측 기간의 성장은 암 치료에서 면역 요법 및 면역 프로파일링의 확대, 액체생검 및 비침습적 종양 프로파일링 방법의 개발, 보다 상세한 종양 특성 분석을 위한 단일 세포 시퀀싱의 채택, 암 검진 및 조기 발견 프로그램의 확대, 희귀암 및 희귀암 아형 프로파일링에 대한 수요 증가에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 종양 프로파일링의 일상 임상으로의 통합, 멀티오믹스 접근법의 발전, 데이터 분석에서 인공지능(AI)과 머신러닝의 통합, 맞춤의료와 표적치료제 개발, 유전체 분석과 차세대 시퀀싱(NGS) 기술의 발전 등이 있습니다.

향후 5년간의 성장률을 13.8%로 예측한 것은 지난번 예측보다 0.2% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 캐나다와 스웨덴에서 수입되는 멀티오믹스 프로파일링 서비스와 인공지능(AI) 기반 종양 분석 소프트웨어에 대한 접근을 제한하고, 개인 맞춤형 치료의 선택권을 위협할 수 있으므로 미국의 정밀의료에 심각한 문제를 야기할 수 있습니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

세계에서 암 발병률 증가는 암 및 종양 프로파일링 시장의 향후 성장을 가속할 것으로 예측됩니다. 암은 체내 특정 세포가 통제할 수 없을 정도로 증식하여 다른 부위로 전이될 가능성이 있는 질병입니다. 암 환자 수가 증가함에 따라 종양 프로파일링에 대한 수요도 증가하여 의사가 질병의 심각성을 평가하는 데 도움이 될 수 있기 때문입니다. 예를 들어 미국에 본사를 둔 전문 기관인 미국 암 협회는 2024년 미국에서 200만 명의 암 환자가 새로 진단되며, 이는 2023년 190만 명에서 증가한 수치라고 보고하고 있습니다. 그 결과, 전 세계에서 암 발병률이 증가하면서 암 및 종양 프로파일링 시장의 성장에 박차를 가하고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계의 암종양 프로파일링 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
  • 최종 용도 산업의 분석
  • 세계의 암종양 프로파일링 시장 : 성장률 분석
  • 세계의 암종양 프로파일링 시장 실적 : 규모와 성장, 2019-2024
  • 세계의 암종양 프로파일링 시장 예측 : 규모와 성장, 2024-2029, 2034F
  • 세계의 암종양 프로파일링 : TAM(Total Addressable Market)

제6장 시장 세분화

  • 세계의 암종양 프로파일링 시장 : 암 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 폐암
  • 유방암
  • 대장암
  • 전립선암
  • 흑색종
  • 난소암
  • 위암
  • 췌장암
  • 갑상선암
  • 기타 암 유형
  • 세계의 암종양 프로파일링 시장 : 기술별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 차세대 시퀀싱(NGS)
  • 중합효소 연쇄 반응(PCR)
  • 면역조직화학(IHC)
  • In Situ 하이브리다이제이션(ISH)
  • 마이크로어레이
  • 기타 테크놀러지
  • 세계의 암종양 프로파일링 시장 : 프로세스 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 유전체학
  • 단백질체학
  • 에피제네틱스
  • 대사체학
  • 기타 유형
  • 세계의 암종양 프로파일링 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 맞춤형 의료
  • 진단
  • 바이오마커 발견
  • 예후
  • 조사 애플리케이션
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 폐암(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 비소세포 폐암(NSCLC)
  • 소세포 폐암(SCLC)
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 유방암(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 호르몬 수용체 양성
  • 삼중음성유방암
  • HER2 양성 유방암
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 대장암(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 대장암
  • 직장암
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 전립선암(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 국소성 전립선암
  • 진행성 전립선암
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 악성 흑색종(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 피부 악성 흑색종
  • 비피부성 흑색종
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 난소암(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 상피성 난소암
  • 비상피성 난소암
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 위암(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 위선 암
  • 위장관 기질 종양(GIST)
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 췌장암(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 외분비 췌장암
  • 신경내분비종양
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 갑상선암(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 유두상 갑상선암
  • 여포성 갑상선암
  • 갑상선 수질암
  • 세계의 암종양 프로파일링 시장 : 서브 세분화, 기타 암 유형(암 유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 신장암
  • 방광암
  • 간암
  • 식도암

제7장 지역별·국가별 분석

  • 세계의 암종양 프로파일링 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 세계의 암종양 프로파일링 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 암종양 프로파일링 시장 : 경쟁 구도
  • 암종양 프로파일링 시장 : 기업 개요
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Caris Life Sciences Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Qiagen Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 대기업과 혁신적 기업

  • Ribomed Biotechnologies Inc.
  • HTG Molecular Diagnostics Inc.
  • NanoString Technologies Inc.
  • NeoGenomics Laboratories Inc.
  • Lucence Health Inc.
  • ACT Genomics Co. LTD
  • Strand Life Sciences
  • IMB Dx Inc.
  • Exact Sciences Corporation
  • Guardant Health
  • Foundation Medicine Inc.
  • Agilent Technologies Inc.
  • Myriad Genetics Inc.
  • Personal Genome Diagnostics Inc.
  • Tempus Labs Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

  • 암종양 프로파일링 시장 2029 : 새로운 기회를 제공하는 국가
  • 암종양 프로파일링 시장 2029 : 새로운 기회를 제공하는 부문
  • 암종양 프로파일링 시장 2029 : 성장 전략
    • 시장 동향에 기반한 전략
    • 경쟁사 전략

제36장 부록

KSA 25.10.02

Cancer tumor profiling is a laboratory testing method designed to analyze a sample of tumor tissue for specific genes, gene mutations, proteins, or other biomarkers. This comprehensive examination aids in treatment planning and provides valuable insights into the likelihood of cancer recurrence or metastasis.

The primary categories of cancer and tumor profiling encompass lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and various other cancer types. Diverse technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, are employed in this process. These technologies cover multiple facets, including genomics, proteomics, epigenetics, metabolomics, and more. Cancer and tumor profiling find applications in personalized medicine, diagnostics, biomarker discovery, prognostics, and research endeavors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cancer tumor profiling market research report is one of a series of new reports from The Business Research Company that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $14.97 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing cancer incidence, growth in precision medicine initiatives and research collaborations, improved cancer diagnostics and early detection methods, availability of a wide range of targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.

The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $25.12 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to expansion of immunotherapy and immunoprofiling in cancer treatment, development of liquid biopsy and non-invasive tumor profiling methods, adoption of single-cell sequencing for more detailed tumor characterization, expansion of cancer screening and early detection programs, and increasing demand for rare and orphan cancer subtype profiling. Major trends in the forecast period include integration of tumor profiling into routine clinical practice, advances in multi-omics approaches, integration of artificial intelligence (AI) and machine learning in data analysis, personalized medicine and targeted therapy development, and advances in genomics and next-generation sequencing (ngs) technologies.

The forecast of 13.8% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. precision medicine by restricting access to multi-omic profiling services and Artificial intelligence(AI)-based tumor analysis software imported from Canada and Sweden, potentially compromising personalized therapy selection. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of cancer worldwide is anticipated to drive the growth of the cancer and tumor profiling market in the future. Cancer is a disease characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas. As the number of cancer cases increases, the demand for tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported that 2 million new cancer cases were diagnosed in the country, an increase from 1.9 million new cases in 2023. Consequently, the increasing incidence of cancer globally is fueling the growth of the cancer and tumor profiling market.

The increasing prevalence of stomach cancer is anticipated to be a key driver for the growth of the cancer and tumor profiling market. Stomach cancer involves the uncontrolled growth of malignant cells in the stomach lining, and cancer and tumor profiling play a crucial role in providing insights into the development of this disease. For example, gastrointestinal stromal tumors (GISTs), though distinct from stomach cancer, can occur in the stomach, and cancer and tumor profiling can help in understanding and treating such cases. As indicated by Cancer Research UK, the incidence of stomach cancer in the UK is expected to decline by 12% between 2023-2025 and 2038-2040. This decline, while positive, highlights the need for continued focus on stomach cancer research and tumor profiling to further address the disease. The growing prevalence of stomach cancer is thus contributing to the expansion of the cancer and tumor profiling market.

Increasing research and development activities are emerging as a significant trend in the cancer and tumor profiling market. Major companies in this sector are prioritizing research and development to meet consumer demands and strengthen their market position. For instance, QIAGEN N.V, a German company specializing in sample and assay technology, recently announced the Conformite Europeenne (CE)-marking and commercialization of the therascreen PIK3CA RGQ PCR Kit in Europe. This diagnostic assay is designed to identify breast cancer patients with PIK3CA mutations, providing crucial information for personalized treatment. The emphasis on research and development activities is a notable trend that is shaping the cancer and tumor profiling market.

In June 2023, Quest Diagnostics, a prominent US-based medical laboratory company, completed the acquisition of Haystack Oncology Inc. for a substantial sum of $450 million. The strategic move by Quest Diagnostics is aimed at broadening access to liquid biopsy technology and strengthening its position in the competitive field of cancer diagnostics. This acquisition is anticipated to augment Quest Diagnostics' research and development capabilities, thereby enhancing its ability to contribute to improved outcomes for cancer patients. Haystack Oncology Inc., based in the United States, is an early-stage oncology company specializing in the development of solid tumor testing technology.

In June 2023, Quest Diagnostics, a US-based medical laboratory firm, acquired Haystack Oncology Inc. for $450 million. This acquisition is intended to broaden access to liquid biopsy technology and enhance Quest Diagnostics' market share in cancer diagnostics by improving research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company focused on developing solid tumor testing technologies aimed at improving outcomes for cancer patients.

Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Tumor Profiling Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer tumor profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer tumor profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer tumor profiling market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types
  • 2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies
  • 3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types
  • 4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications
  • Subsegments:
  • 1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)
  • 2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer
  • 3) By Colorectal Cancer: Colon Cancer; Rectal Cancer
  • 4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer
  • 5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma
  • 6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer
  • 7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)
  • 8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors
  • 9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer
  • 10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Caris Life Sciences; Thermo Fisher Scientific Inc.; Illumina Inc.; Qiagen; Ribomed Biotechnologies Inc.; HTG Molecular Diagnostics Inc.; NanoString Technologies Inc.; NeoGenomics Laboratories Inc.; Lucence Health Inc.; ACT Genomics Co. LTD; Strand Life Sciences; IMB Dx Inc.; Exact Sciences Corporation; Guardant Health; Foundation Medicine Inc.; Agilent Technologies Inc.; Myriad Genetics Inc.; Personal Genome Diagnostics Inc.; Tempus Labs Inc.; ArcherDX Inc.; Natera Inc.; Bio-Rad Laboratories Inc.; Genetron Health; NantHealth Inc.; Resolution Bioscience; Genomic Testing Cooperative; OncoDNA; Strata Oncology Inc.; Genuity Science; RareCyte Inc.; Inivata Limited; Cepheid
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Tumor Profiling Market Characteristics

3. Cancer Tumor Profiling Market Trends And Strategies

4. Cancer Tumor Profiling Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cancer Tumor Profiling Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cancer Tumor Profiling PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cancer Tumor Profiling Market Growth Rate Analysis
  • 5.4. Global Cancer Tumor Profiling Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cancer Tumor Profiling Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cancer Tumor Profiling Total Addressable Market (TAM)

6. Cancer Tumor Profiling Market Segmentation

  • 6.1. Global Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Ovarian Cancer
  • Stomach Cancer
  • Pancreatic Cancer
  • Thyroid Cancer
  • Other Cancer Types
  • 6.2. Global Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Microarray
  • Other Technologies
  • 6.3. Global Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Genomics
  • Proteomics
  • Epigenetics
  • Metabolomics
  • Other Types
  • 6.4. Global Cancer Tumor Profiling Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Personalized Medicine
  • Diagnostics
  • Biomarker Discovery
  • Prognostics
  • Research Applications
  • 6.5. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Lung Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)
  • 6.6. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Breast Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Receptor-Positive
  • Triple-Negative Breast Cancer
  • HER2-Positive Breast Cancer
  • 6.7. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Colorectal Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Colon Cancer
  • Rectal Cancer
  • 6.8. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Prostate Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Localized Prostate Cancer
  • Advanced Prostate Cancer
  • 6.9. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Melanoma, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cutaneous Melanoma
  • Non-Cutaneous Melanoma
  • 6.10. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Ovarian Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Epithelial Ovarian Cancer
  • Non-Epithelial Ovarian Cancer
  • 6.11. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Stomach Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gastric Adenocarcinoma
  • Gastrointestinal Stromal Tumors (GISTs)
  • 6.12. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Pancreatic Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Exocrine Pancreatic Cancer
  • Neuroendocrine Tumors
  • 6.13. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Thyroid Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Papillary Thyroid Cancer
  • Follicular Thyroid Cancer
  • Medullary Thyroid Cancer
  • 6.14. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Other Cancer Types, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Kidney Cancer
  • Bladder Cancer
  • Liver Cancer
  • Esophageal Cancer

7. Cancer Tumor Profiling Market Regional And Country Analysis

  • 7.1. Global Cancer Tumor Profiling Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cancer Tumor Profiling Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Tumor Profiling Market

  • 8.1. Asia-Pacific Cancer Tumor Profiling Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Tumor Profiling Market

  • 9.1. China Cancer Tumor Profiling Market Overview
  • 9.2. China Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Tumor Profiling Market

  • 10.1. India Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Tumor Profiling Market

  • 11.1. Japan Cancer Tumor Profiling Market Overview
  • 11.2. Japan Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Tumor Profiling Market

  • 12.1. Australia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Tumor Profiling Market

  • 13.1. Indonesia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Tumor Profiling Market

  • 14.1. South Korea Cancer Tumor Profiling Market Overview
  • 14.2. South Korea Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Tumor Profiling Market

  • 15.1. Western Europe Cancer Tumor Profiling Market Overview
  • 15.2. Western Europe Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Tumor Profiling Market

  • 16.1. UK Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Tumor Profiling Market

  • 17.1. Germany Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Tumor Profiling Market

  • 18.1. France Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Tumor Profiling Market

  • 19.1. Italy Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Tumor Profiling Market

  • 20.1. Spain Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Tumor Profiling Market

  • 21.1. Eastern Europe Cancer Tumor Profiling Market Overview
  • 21.2. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Tumor Profiling Market

  • 22.1. Russia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Tumor Profiling Market

  • 23.1. North America Cancer Tumor Profiling Market Overview
  • 23.2. North America Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Tumor Profiling Market

  • 24.1. USA Cancer Tumor Profiling Market Overview
  • 24.2. USA Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Tumor Profiling Market

  • 25.1. Canada Cancer Tumor Profiling Market Overview
  • 25.2. Canada Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Tumor Profiling Market

  • 26.1. South America Cancer Tumor Profiling Market Overview
  • 26.2. South America Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Tumor Profiling Market

  • 27.1. Brazil Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Tumor Profiling Market

  • 28.1. Middle East Cancer Tumor Profiling Market Overview
  • 28.2. Middle East Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Tumor Profiling Market

  • 29.1. Africa Cancer Tumor Profiling Market Overview
  • 29.2. Africa Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Tumor Profiling Market Competitive Landscape And Company Profiles

  • 30.1. Cancer Tumor Profiling Market Competitive Landscape
  • 30.2. Cancer Tumor Profiling Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Caris Life Sciences Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Qiagen Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Tumor Profiling Market Other Major And Innovative Companies

  • 31.1. Ribomed Biotechnologies Inc.
  • 31.2. HTG Molecular Diagnostics Inc.
  • 31.3. NanoString Technologies Inc.
  • 31.4. NeoGenomics Laboratories Inc.
  • 31.5. Lucence Health Inc.
  • 31.6. ACT Genomics Co. LTD
  • 31.7. Strand Life Sciences
  • 31.8. IMB Dx Inc.
  • 31.9. Exact Sciences Corporation
  • 31.10. Guardant Health
  • 31.11. Foundation Medicine Inc.
  • 31.12. Agilent Technologies Inc.
  • 31.13. Myriad Genetics Inc.
  • 31.14. Personal Genome Diagnostics Inc.
  • 31.15. Tempus Labs Inc.

32. Global Cancer Tumor Profiling Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Tumor Profiling Market

34. Recent Developments In The Cancer Tumor Profiling Market

35. Cancer Tumor Profiling Market High Potential Countries, Segments and Strategies

  • 35.1 Cancer Tumor Profiling Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cancer Tumor Profiling Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cancer Tumor Profiling Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제